GEMIN X BIOTECHNOLOGIES
Gemin X Biotechnologies Inc. operates as a biopharmaceutical company .
Similar Organizations
ppm.Ingredients
ppm.Ingredients operates as a biopharmaceutical company.
RecombinoGen Ltd.
RecombinoGen Ltd. operates as a biopharmaceutical company.
Current Advisors List
More informations about "Gemin X Biotechnologies"
Gemin X Pharmaceuticals - Crunchbase Company Profile & Funding
Gemin X Pharmaceuticals is dedicated to the discovery, development and commercialization of novel, targeted cancer therapeutics to improve the lives of patients. Gemin X's research on the …See details»
Gemin X Biotechnologies - Crunchbase Company Profile & Funding
Organization. Gemin X Biotechnologies . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. ... Alternatives and possible competitors to …See details»
Gemin X Biotechnologies - Ownership and Business Overview
Mar 22, 2011 Gemin X Biotechnologies Inc. is a biopharmaceutical company that engages in the discovery and development of small molecule cancer therapeutics based on the regulation of …See details»
GeminX | BDC.ca
Biotechnology Investment year. 2001. Fund. Healthcare Venture Fund. Learn more Lead. Ela Borenstein Vice President. View profile. About the company. Gemin X specialized in the …See details»
Gemin X - Products, Competitors, Financials, Employees, …
Gemin X Pharmaceuticals is dedicated to the discovery, development and commercialization of novel, targeted cancer therapeutics to improve the lives of patients. Use the CB Insights …See details»
Gemin X Pharmaceuticals - PitchBook
Jul 1, 2008 Gemin X Pharmaceuticals General Information Description. Manufacturer of cancer therapeutics and drugs in the United States. The company provides GX15-070, a small molecule that reinitiates programmed …See details»
Gemin X Biotechnologies: Drug pipelines, Patents, Clinical trials
Jun 28, 2023 Explore Gemin X Biotechnologies with its drug pipeline, therapeutic area, technology platform, 1 news, and 6 literature, Drug:Obatoclax mesylate, Anti-latent virus ...See details»
Cephalon to Spend $225M to Purchase Gemin X for Phase II SCLC …
Mar 22, 2011 Pan-bcl2 inhibitor obatoclax is also undergoing Phase I evaluation against multiple myeloma, NHL, and CLL.See details»
Gemin X Biotechnologies - Contacts, Employees, Board
Gemin X Biotechnologies Inc. operates as a biopharmaceutical company .See details»
Cephalon scoops up cancer drugs in $525M Gemin X buyout
Mar 22, 2011 Gemin X will proceed as a wholly-owned subsidiary, adding its late-stage work to Cephalon, which has been working on some of the same cancer targets and now has an …See details»
Gemin X Pharmaceuticals - Fierce Biotech
Jul 7, 2008 Pharma development chief takes on role of biotech entrepreneur Over the past 20 years, Glenn Gormley, M.D., Ph.D., rose to a high altitude in the world of big pharma drug …See details»
Emerging Drug Developer: Gemin X Pharmaceuticals
Jul 7, 2008 Gemin X Pharmaceuticals Over the past 20 years, Glenn Gormley, M.D., Ph.D., rose to a high altitude in the world of big pharma drug development. | Gemin X Pharmaceuticals …See details»
Facilitating the development of anticancer drugs - McGill University
May 12, 2003 Structural biologists from McGill University have discovered a mechanism that sheds light on how certain proteins regulate programmed cell death (also known as …See details»
Gemin X Biotechnologies - Tech Stack, Apps, Patents & Trademarks
Gemin X Biotechnologies Inc. operates as a biopharmaceutical company .See details»
Gemin X Biotechnologies Inc. Announces Publication of ... - BioSpace
Mar 7, 2007 MONTREAL & MALVERN, Pa.--(BUSINESS WIRE)--Gemin X announced today that a report published in the online version of the journal Blood demonstrated that its lead …See details»
Cephalon Announces Definitive Agreement to Acquire Gemin X
Mar 22, 2011 Gemin X's lead product candidate, obatoclax (GX15-070), is a pan Bcl-2 inhibitor with particular potency for the dominant protein Mcl-1 and is currently completing a …See details»
Research programme: telomere capping inhibitors - Gemin X
Gemin X and Exelgen (formerly Tripos Discovery Research) were collaborating on the discovery of small molecule compounds that disrupt telomere capping in cancerSee details»
Gemin X Pharmaceuticals Closes $38 Million Series C Financing
Jun 30, 2008 Gemin X Pharmaceuticals, Inc. Closes $38 Million Series C Financing to Advance Lead Cancer Drug, Obatoclax, Into Registration Trials MALVERN, Pa. & MONTREAL -- …See details»
Phase 1 clinical data shows Gemin X's GX15-070 improves chronic ...
Dec 13, 2005 Gemin X is currently conducting a Phase 1 clinical trial with GX15-070 in patients with advanced, refractory solid tumours and expects initial results in 2006. The company plans …See details»
Gemin X books $16M Series D as it pursues PhIIb cancer trial
Apr 20, 2010 Malvern, PA-based Gemin X Pharmaceuticals has rounded up $16 million in a Series D round led by two existing investors. The money will be put to use advancing the …See details»